|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
36
|
|
pubmed:dateCreated |
2006-10-11
|
|
pubmed:abstractText |
The MISCAN-Fadia model was used to analyze the impact of screening and adjuvant treatment on U.S. breast cancer mortality between 1975 and 2000. MISCAN-Fadia uses the concept of "fatal diameter" to model survival and screening benefit and is based on continuous tumor growth. It consists of four major components: population, natural history, screening, and treatment. Population parameters were quantified using U.S. population data. Most natural history and screening parameters were fitted to the Swedish Two County screening trial data; some were based on Surveillance, Epidemiology, and End Results data. Adjuvant treatment parameters were quantified using data from the Early Breast Cancer Trialists' Collaborative Group's meta-analysis. The simulated trend in incidence matches the observed trend reasonably well; the simulated mortality is equal to the observed in 1975 but becomes increasingly too high in 2000. We estimate that screening leads to a 15% and adjuvant treatment to a 21% mortality reduction in the year 2000.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1052-6773
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
56-65
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17032895-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17032895-Breast Neoplasms,
pubmed-meshheading:17032895-Chemotherapy, Adjuvant,
pubmed-meshheading:17032895-Cohort Studies,
pubmed-meshheading:17032895-Disease Progression,
pubmed-meshheading:17032895-Female,
pubmed-meshheading:17032895-Humans,
pubmed-meshheading:17032895-Incidence,
pubmed-meshheading:17032895-Mammography,
pubmed-meshheading:17032895-Mass Screening,
pubmed-meshheading:17032895-Meta-Analysis as Topic,
pubmed-meshheading:17032895-Models, Statistical,
pubmed-meshheading:17032895-Neoplasm Invasiveness,
pubmed-meshheading:17032895-Predictive Value of Tests,
pubmed-meshheading:17032895-Sensitivity and Specificity,
pubmed-meshheading:17032895-Survival Rate,
pubmed-meshheading:17032895-Sweden,
pubmed-meshheading:17032895-United States
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
The MISCAN-Fadia continuous tumor growth model for breast cancer.
|
|
pubmed:affiliation |
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, N.I.H., Extramural
|
